Bard LifeStent and Lutonix DCB for Treatment of Long Lesions in Femoropopliteal Arteries

A Prospective, Multicenter, Single-Arm, Post-Market Study Using the Lutonix Drug Coated Balloon for Post-Dilatation of the Bard LifeStent Vascular Stent for Treatment of Long Lesions in Femoropopliteal Arteries

Objective of this study is to evaluate the safety and efficacy of Lutonix 035 Drug Coated Dilatation PTA Catheter with Bard LifeStent Vascular Stent (hereinafter referred to as LifeStent) for treatment of long (10-24 cm) lesions in the SFA and/or proximal popliteal artery.

Study Overview

• Status: Completed
• Conditions: Peripheral Artery Disease
• Intervention / Treatment: Device: Lutonix Drug Coated Balloon

Detailed Description

The study will observe subjects presenting with claudication or ischemic rest pain (Rutherford category 2-4) and long (10-24 cm in length) native lesions in the infra-inguinal segment (superficial femoral artery [SFA] and/or proximal popliteal artery) who are candidates for stenting and pre-/post-dilatation with Drug Coated Balloon (DCB).

• Study Type: Observational
• Enrollment (Actual): 149

Contacts and Locations

Study Locations

• Germany
  • Arnsberg, Germany, 59755
    • Klinikum Arnsberg
  • Bad Bevensen, Germany, 29549
    • Herz- und Gefässzentrum Bad Bevensen
  • Bad Krozingen, Germany, 79189
    • Universitäts-Herzzentrum Freiburg Bad Krozingen
  • Hamburg, Germany, 22527
    • Angiologikum Hamburg
  • Immenstadt, Germany, 87509
    • Klinik Immenstadt
  • Kassel, Germany, 34125
    • Klinikum Kassel
  • Lübeck, Germany, 23538
    • UKSH - Campus Lübeck
  • Rosenheim, Germany, 83022
    • RoMed Klinikum Rosenheim
  • Sonneberg, Germany, 96515
    • Gefäßzentrum Sonneberg
  • Weiden, Germany, 92637
    • Klinikum Weiden
• Greece
  • Patras, Greece, 26504
    • University General Hospital of Patras
• Poland
  • Sanok, Poland, 38-500
    • SPZOZ Sanok

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Hospital Patients

Description

Inclusion Criteria: Subjects will be included if all of the following inclusion criteria apply:

1. Age ≥18 years;
2. The subject is legally competent and able to understand the information on the study, has been informed of the nature, the scope and the relevance of the study, voluntarily agrees to participation and the study's provisions, and has duly signed the Informed Consent Form (ICF);
3. Rutherford Category 2-4;
4. Target de novo lesion(s) or non-stented restenotic lesion(s) has angiographic evidence of ≥50% stenosis or occlusion (by visual estimate) and is amenable to treatment with LifeStent® and Lutonix DCB;
5. Patients must be able to be treated with Lutonix DCB and LifeStent®;
6. Total Lutonix DCB treated segment(s) of 10-24 cm in length;
7. Target vessel reference diameter is 4.0-7.0 mm (by visual estimate) and able to be treated with available device size matrix;
8. At least one patent native outflow artery to the ankle free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of outflow disease is NOT permitted; treatment of in-flow disease is permitted prior to treatment with LifeStent®).
9. No other prior vascular interventions (including contralateral limb) within 2 weeks before and/or planned 30 days after the protocol treatment, with the exception of remote common femoral patch angioplasty separated by at least 2 cm from the target lesion;
10. Female subjects of childbearing potential have a negative urine or serum pregnancy test within 7 days prior to index procedure;
11. Lesion location starts ≥1 cm below the common femoral bifurcation and terminates distally ≤2 cm below the tibial plateau AND ≥1 cm above the origin of the tibioperoneal trunk.

Exclusion Criteria:

1. Pregnant, lactating, or planning on becoming pregnant or men intending to father children;
2. Contraindication to Lutonix DCB or LifeStent® per current IFU;
3. Life expectancy of <1 year;
4. Inability to take required antiplatelet/anticoagulant medications per the LifeStent® and Lutonix DCB IFU, or known contraindication (including allergic reaction) or sensitivity to contrast media, nickel, titanium or tantalum that cannot be adequately managed with pre- and post-procedure medication;
5. Intended treatment of outflow disease during the index procedure;
6. Intended use of laser, atherectomy or cryoplasty during index procedure;
7. Sudden symptom onset, acute vessel occlusion, or acute or subacute thrombus in target vessel;
8. History of stroke within 3 months;
9. History of myocardial infarction, thrombolysis or angina within 2 weeks of enrollment;
10. Participation in an investigational drug or another investigational device study until this study's (Lutonix LifeStent® Study) primary endpoint is reached or previous enrollment in this study;
11. Another medical condition, which, in the opinion of the Investigator, may cause the patient to be noncompliant with the CIP or confound data interpretation;
12. Target vessel and/or lesion involves a previously placed stent.

Study Plan

How is the study designed?

Design Details

• Observational Models: Cohort
• Time Perspectives: Prospective

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Lutonix Drug Coated Balloon; Paclitaxel coated balloon catheter	Device: Lutonix Drug Coated Balloon; Subject will receive treatment with the Lutonix Drug Coated Balloon

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary patency at 12 months.	Primary patency is defined as the absence of target lesion restenosis and freedom from target lesion revascularization.	12 months
Freedom from the composite endpoint of death, index limb amputation, and target vessel revascularization at 30 days.	Freedom from the composite endpoint of death, index limb amputation, and target vessel revascularization at 30 days.	30 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Procedural success	Defined as attainment of ≤30% residual stenosis by quantitative angiography immediately after intervention in the absence of peri-procedural complications.	Immediately after Intervention
Technical success	Defined as attainment of ≤30% residual stenosis by quantitative angiography.	Immediately after intervention
Device success	Defined as successful delivery of the DCB to the target lesion and performance when used according to the clinical investigational plan.	Immediately after intervention
Freedom from Target Lesion Revascularization after 30 days, and 6, 12 and 24 months post-index procedure.	Absence of Target Lesion Revascularization.	30 days, 6, 12 and 24 months
Freedom from TVR after 30 days, and 6, 12 and 24 months post-index procedure.	Absence of Target Vessel Revascularization.	30 days, 6, 12 and 24 months
Change in resting ankle brachial index (ABI) from baseline to 30 days, and 6, 12 and 24 months post-index procedure	The ABI values will be recorded and compared to the baseline values. The ABI is the ratio of the blood pressure at the ankle to the blood pressure in the upper arm. A ratio of 0.9-1.3 is in the normal range. Lower ratios indicate bad blood perfusion of the leg.	30 days, 6, 12 and 24 months
Change in Rutherford Classification from baseline to 30 days, and 6, 12 and 24 months post-index procedure	Patients are enrolled with a Rutherford grade of 2-4 for their target leg. The Rutherford scale is an indicator for the severity of Peripheral Vascular Disease: 0 = no symptoms, 6 = functional foot is no longer salvageable (leading to foot amputation).	30 days, 6, 12 and 24 months
All-cause death	Death by any cause will be counted.	30 days, 6, 12 and 24 months
Amputation (above the ankle)-free survival	Amputations above the ankle of the target leg will be counted.	30 days, 6, 12 and 24 months
Target limb reintervention for treatment of thrombosis of target vessel or embolization to its distal vasculature	Thrombosis in the target vessel and embolizations below the target lesion will be analazed separately from other stenoses.	30 days, 6, 12 and 24 months

Collaborators and Investigators

• Sponsor: C. R. Bard
• Investigators: Principal Investigator: Thomas Zeller, Prof.

Study record dates

Study Major Dates

• Study Start (Actual): October 1, 2014
• Primary Completion (Actual): September 1, 2017
• Study Completion (Actual): October 2, 2018

Study Registration Dates

• First Submitted: October 28, 2014
• First Submitted That Met QC Criteria: October 29, 2014
• First Posted (Estimate): October 30, 2014

Study Record Updates

• Last Update Posted (Actual): October 9, 2019
• Last Update Submitted That Met QC Criteria: October 7, 2019
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Arteriosclerosis; Arterial Occlusive Diseases; Atherosclerosis; Peripheral Vascular Diseases; Peripheral Arterial Disease
• Other Study ID Numbers: CL0022-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No